The plasma digoxin concentration that will result from a given dose of the drug can be predicted at best with only 34% accuracy, although knowledge of a previous concentration improves the ability to predict subsequent concentrations. In outpatients taking a fixed daily dosage, a steady state plasma digoxin concentrations vary widely (between 0 5 and 3 5 nmol/l). This means that if a target plasma digoxin concentration is desirable measuring the concentration may be useful in tailoring dosages to individual requirements.
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In this article we apply to digoxin the criteria (described in the previous article on measuring plasma drug concentrations) which must be fulfilled in part or in full before the measurement of its plasma concentration can be considered worth while.
Criteria for measurement
Ve'ntricular rate i'n atrial fibrillation before (top) after (bottom) taking digoxin.
uorrelation between percentage cnange in ventricular rate in atrial fibrillation and plasma digoxin concentration.
Is there difficulty in interpreting clinical evidence ofthe therapeutic or toxic effects?
In patients with atrial fibrillation the slowing of the ventricular rate is usually a good guide to the therapeutic effect of digoxin. However, in patients with congestive cardiac failure with sinus rhythm who are taking digoxin for its positive inotropic effect there is no easily measurable end point by which to assess the therapeutic response. Furthermore In the case of atrial fibrillation there is good evidence that increasing the concentration of digoxin within the therapeutic range produces an increase in its effect of slowing the ventricular rate.
In patients with sinus rhythm a relation between the plasma concentration of digoxin and its therapeutic effect has not been clearly established. Generally a satisfactory therapeutic response is most likely to be achieved when plasma digoxin concentrations are between 1 0 nmol/I and 2 6 or 3 8 nmolIl. These limits are based, at least in part, on observations outside this range: the risk of digoxin toxicity increases at concentrations above 2 6 nmol/l and is almost invariable at concentrations greater than 3 8 nmol/l, and it is difficult to detect any effect of digoxin when the plasma concentration is below 1 0 nmolIl. 
Measurement techniques
Most studies have shown a significant difference between the mean plasma digoxin concentration in groups of patients with toxicity and the mean concentration in groups without toxicity. The chief problem lies in making the diagnosis of digoxin toxicity in the individual patient. There is no doubt that the plasma concentration on its own is not always sufficient in deciding whether or not a patient has digoxin toxicity. The decision can be made only by considering the plasma digoxin concentration in the light of other clinical and biochemical information. Toxicity is likely when: * The plasma digoxin concentration is greater than 3 8 nmol/l * The plasma digoxin concentration is less than 3 8 nmol/I and the plasma potassium concentration is less than 3 5 mmol/l * The plasma digoxin concentration is less than 3 -8 nmolI and there are any two of the following:
Plasma potassium >5 mmol/l Plasma creatinine >150 iimol/l Age >60 years Daily maintenance dose >6 pg/kg (for example, 375 pg for a 60 kg patient)
Thus in a patient suspected of having toxicity the plasma potassium and digoxin concentrations and any factors which may alter the patient's sensitivity to digoxin should be considered. If these all support the diagnosis oftoxicity the digoxin should be stopped. Ifthe diagnosis is still in doubt the patient should be carefully observed while continuing to take digoxin, but the situation must be reviewed and digoxin should be stopped if necessary. It is certainly better to withhold digoxin from a patient who does not have toxicity than to continue treatment in a patient who does.
For children over 1 year of age the same plasma concentrations are associated with toxicity as in adults. In infants and neonates, however, there is no clear cut pattern and plasma digoxin concentrations can be difficult to interpret.
Is digoxin metabolised to active metabolites?
Most patients metabolise less than 20% of digoxin, and so active metabolites are relatively unimportant. However, about 10% of patients metabolise up to 55%, both by hydrolysis to digoxigenin and to its bisdigitoxosides and monodigitoxosides, all of which have pharmacological activity, and by reduction to dihydrodigoxin, which is relatively inactive. This conversion is thought to occur in the bowel through an effect of gut bacteria, and in those patients in whom it occurs digoxin metabolism may be reduced by antibiotics such as erythromycin and tetracyclines.
In theory, if digoxin was assayed by measuring the pharmacological activity of all the components (both digoxin and its metabolites) the variation in digoxin would not be a problem. But the types of immunoassay routinely used do not necessarily measure all the metabolites, and in certain cases might give a spuriously low plasma concentration of active cardiac glycosides. This may explain some cases of digoxin toxicity in patients with plasma concentrations in the therapeutic range. 
